News TAE raises $40m to develop new targeted radiotherapy Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.
Views & Analysis Kick-starting innovation in Glioblastoma Can risk-sharing and real-world evidence can provide traction in treating the brain cancer Glioblastoma?
News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face